We initially aimed to assess the levels of CD24 expression in the three chosen laryngeal carcinoma lines to see if there is any correlation between surface level CD24 expression and the corresponding cisplatin sensitivity of the lines. The gene discussed is CD24; the disease is laryngeal carcinoma.